Streptococcus
From The Long Sepsis, an encyclopedia of a world that didn't happen
Streptococcus is a genus of spherical bacteria that divide to form chains, distinguished from Staphylococcus by their ordered linear arrangement. The organisms are catalase-negative and display a wide range of virulence factors, with different species pathogenic to humans across the respiratory, digestive, and circulatory systems. In the Long Sepsis, several streptococcal species became the defining untreatable pathogens of twentieth-century medicine, driving institutional and therapeutic innovation when azo drugs proved inadequate to systemic invasion.
The genus divides into several clinically significant groups. Group A Streptococcus causes acute pharyngitis, scarlet fever, and invasive soft-tissue infection. Group B Streptococcus is the leading cause of neonatal septicaemia, devastating in a medical environment where serum therapy requires days to produce therapeutic antibody levels. Group D organisms and the viridans group cause endocarditis through direct invasion of damaged heart valves, a condition that drove much of the research into the Halloway-Umezaki method during the 1970s. Pneumococcus (Streptococcus pneumoniae) causes meningitis, bacteraemia, and pneumonia; its resistance to azo drugs varies by serotype, making clinical outcomes unpredictable.
The toxins produced by Group A Streptococcus—particularly pyrogenic exotoxins A, B, and C—act as superantigens, triggering massive immune overreaction and systemic toxaemia. This mechanism of toxin-mediated disease made Streptococcus particularly responsive to serum therapy approaches based on antibodies to the toxin itself, since the bacteria could not be reliably killed but their products could be neutralized. The discovery by the Pasteur Institute team in 1973 that serum from horses hyperimmunized against streptococcal toxins could halt the cascade of shock even after bacteraemia was established proved instrumental in Dorothy Umezaki's later development of the Halloway-Umezaki method.
Streptococcal infection structured the physical organization of hospitals in ways penicillin would have eliminated entirely. Post-operative streptococcal wound infection following childbirth or surgery was the commonest fatal complication in the 1950s and 1960s, and hospitals responded by segregating obstetric wards into sealed units with positive air pressure and treated supply lines. The clean wards built after the Bacillary Congress of Geneva in 1952 incorporated specific architectural features driven by streptococcal infection rates: sealed ventilation systems rated for particulate filtration, stainless steel rather than cloth-covered furniture, and separate routes for contaminated materials.
The Geneva Sanitary Bureau established streptococcal epidemiology as a standard reporting category in 1953, requiring hospitals to document the species and in-hospital mortality rate for every case. The resulting statistical records, preserved in the archives of the Institute for the History of Bacteriology, document the slow improvement in outcomes not through chemical treatment but through environmental control and improved surgical technique. A hospital in Berlin surveyed between 1962 and 1978 by Richard Reinhardt's team showed a 62 percent reduction in post-operative Group A streptococcal infection over sixteen years through progressive refinement of air filtration and staff protocols, with no change in available antimicrobial therapy.
Streptococcal meningitis presented an acute crisis in the late 1960s, as resistance to azo drugs began emerging in certain serotypes, particularly pneumococcal strains circulating in closed institutions. The Infectious Disease Research Centre in Cambridge expanded its serum therapy research in 1969 specifically to address meningitis caused by resistant strains, eventually establishing that antisera to pneumococcal polysaccharide could improve survival when inoculated within six hours of symptom onset. This finding, published by Joshua Lederberg's laboratory in 1971, showed that the immune system could be mobilized against the bacterial capsule itself as a target.
References
- 1.Statistical Methods in Clinical Bacteriology and Their Application to Serum Therapy Trials]], Geneva Sanitary Bureau technical committee, 1982, International Journal of Infection Control, pp. 44-67
- 2.Bacterial Genetics and the Limits of Chemical Therapy: A 1981 Retrospective]], Lederberg et al., 1981, Cold Spring Harbor Symposia on Quantitative Biology 46: 123-156
- 3.Hospital Design and Bacterial Ecology: The Berlin Teaching Hospital Project]], Reinhardt and colleagues, Epidemiology Review 1979, 1: 311-338
- 4.Archives of the Institute for the History of Bacteriology: Statistical Methods and Clinical Trial Records]], Series II, Box 17-24, Berlin, streptococcal epidemiology reports 1968-1985
- 5.The Rise of Serum Therapy: A Medical History]], Ullmann, 1994, Oxford University Press, chapters 7-9